Healthcare • Investment • Impact
Most funds raise capital and then go looking for deals. Veracor Capital spent 20 years building KureCare, EliteMD, Pure Pak, and the clinical infrastructure — then formed a fund to scale what already works.
Healthcare visionary, veteran, and author exploring the intersection of medicine, leadership, and truth.
2025 was a build year for Veracor Capital. Here's why intentional infrastructure investment — not flashy growth numbers — creates the strongest foundations for compounding returns.
Signal-Based Medicine is Veracor Capital's core IP moat — a methodology that treats chronic disease at the root cause rather than managing symptoms. Here's what investors need to know.
Healthcare private equity operates under fundamentally different dynamics than traditional PE. Here's why that matters for sophisticated investors seeking uncorrelated returns.
EB-5 investors seeking U.S. permanent residency can deploy capital into healthcare projects that create jobs, improve communities, and generate returns. Here's how it works.
After decades of research and clinical observation, patterns emerge in our healthcare system that fundamentally challenge conventional approaches. Discover why Signal-Based Medicine represents the future of personalized treatment.
Why we're committed to bringing Signal-Based Medicine to veterans and first responders at no cost.
The body communicates through biological signals. Learning to read and respond to these signals is revolutionizing patient outcomes.
What NASCAR taught me about leadership, risk, and the importance of a well-oiled team.
The difference between companies that survive and those that thrive comes down to a few key principles.
What it means to live the KureLife and why thousands are joining this movement.
An investigative look at the systems that shape—and sometimes fail—modern healthcare.
The research, the revelations, and the reason I had to write this trilogy.
We use cookies to enhance your experience and analyze site traffic. By continuing to browse, you agree to our use of cookies.
